Nanosonics Limited (AU:NAN)
ASX:NAN
NAN Stock Chart & Stats
AU$3.75
AU$0.07(2.30%)
At close: 4:00 PM EST
AU$3.75
AU$0.07(2.30%)
Day’s Range― - ―
52-Week RangeAU$3.21 - AU$5.08
Previous CloseN/A
Volume330.71K
Average Volume (3M)506.11K
Market Cap
AU$1.14B
Enterprise ValueAU$986.14M
Total Cash (Recent Filing)AU$159.83M
Total Debt (Recent Filing)AU$9.88M
Price to Earnings (P/E)31.3
Beta0.45
Next Earnings
Sep 01, 2026EPS Estimate
0.03Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.03
Shares Outstanding303,360,960
10 Day Avg. Volume525,818
30 Day Avg. Volume506,110
Financial Highlights & Ratios
PEG Ratio0.95
Price to Book (P/B)5.85
Price to Sales (P/S)6.18
P/FCF Ratio34.85
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
AU$4.21Price Target Upside12.15% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering4
EPS Forecast (FY)0.05
Revenue Forecast (FY)AU$211.45M
Bulls Say, Bears Say
Bulls Say
High Gross Margins & ProfitabilitySustained very high gross margins (78%+) and improving net margin create durable earnings power. This margin profile supports reinvestment in product development, funds recurring-consumables economics and buffers pricing/mix swings, enabling consistent operating leverage over months.
Recurring Consumables And Installed Base GrowthThe razor‑and‑blades model yields steady, usage‑driven consumables sales tied to an expanding installed base. Durable 6–9% growth in installations and consumables increases annuity-like revenue, improving visibility of midterm cash flows and margin scalability as installed units drive repeat purchases.
Very Strong Balance Sheet And Cash PositionMinimal leverage and a large cash balance provide lasting financial flexibility to fund CORIS commercialization, product investments, buybacks or absorb temporary headwinds. Low leverage reduces refinancing risk and preserves capacity for strategic investments over the next 2–6 months.
Bears Say
FX Sensitivity And Reported Earnings ImpactMeaningful multi‑currency exposure means currency moves can materially affect reported revenue and profits despite hedging. Over months, persistent AUD/USD shifts can erode reported growth and margin progress, complicating comparability and raising execution risk for financial targets.
CORIS Commercialization Raises Near‑term Cash And OpExCommercializing CORIS requires upfront inventory, marketing and sales investment, which raises OpEx and consumes cash before material revenue arrives. This prolongs payback on commercialization spend and increases execution risk if adoption or regulatory timing slips in the coming quarters.
Pricing And Mix Pressure From Upgrade DealsVolume-driven upgrade agreements and a shift toward lower‑ASP models compress capital revenue per unit. Over months, sustained ASP moderation can reduce capital revenue growth and spare‑parts pull‑through, pressuring top-line momentum and requiring stronger consumables or service growth to offset weaker device revenues.
Nanosonics Limited News
NAN FAQ
What was Nanosonics Limited’s price range in the past 12 months?
Nanosonics Limited lowest share price was AU$3.21 and its highest was AU$5.08 in the past 12 months.
What is Nanosonics Limited’s market cap?
Nanosonics Limited’s market cap is AU$1.14B.
When is Nanosonics Limited’s upcoming earnings report date?
Nanosonics Limited’s upcoming earnings report date is Sep 01, 2026 which is in 152 days.
How were Nanosonics Limited’s earnings last quarter?
Nanosonics Limited released its earnings results on Feb 23, 2026. The company reported AU$0.031 earnings per share for the quarter, the consensus estimate of AU$0.031 by AU$0.
Is Nanosonics Limited overvalued?
According to Wall Street analysts Nanosonics Limited’s price is currently Undervalued.
Does Nanosonics Limited pay dividends?
Nanosonics Limited does not currently pay dividends.
What is Nanosonics Limited’s EPS estimate?
Nanosonics Limited’s EPS estimate is 0.03.
How many shares outstanding does Nanosonics Limited have?
Nanosonics Limited has 303,360,960 shares outstanding.
What happened to Nanosonics Limited’s price movement after its last earnings report?
Nanosonics Limited reported an EPS of AU$0.031 in its last earnings report, expectations of AU$0.031. Following the earnings report the stock price went down -9.89%.
Which hedge fund is a major shareholder of Nanosonics Limited?
Currently, no hedge funds are holding shares in AU:NAN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Nanosonics Limited Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
AU$4.21 (12.15% Upside)
AU$4.21 (12.15% Upside)
Blogger Sentiment
Bullish
AU:NAN Sentiment 100%
Sector Average ―
Sector Average ―
Insider Transactions
Bought Shares
Worth $35.3K over
the Last 3 Months
the Last 3 Months
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
49.48%
12-Months-Change
Fundamentals
Return on Equity
9.57%
Trailing 12-Months
Asset Growth
17.94%
Trailing 12-Months
Company Description
Nanosonics Limited
Nanosonics Limited, together with its subsidiaries, operates as an infection prevention company in Australia and internationally. The company engages in the manufacturing and distribution of the trophon ultrasound probe disinfector, and its associated consumables and accessories; and research, development, and commercialization of infection control and decontamination products and related technologies. It provides trophon2, an ultrasound probe high level disinfection device; trophon EPR, a low temperature high level disinfection solution for intra-cavity ultrasound probes; and Nanosonics AuditPro, an infection control workflow compliance management solution. Nanosonics Limited was incorporated in 2000 and is headquartered in Macquarie Park, Australia.
NAN Company Deck
NAN Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call presented a substantially positive operational and financial picture: revenue and recurring revenue grew ~9% YoY, operating margin expanded materially (27%) with tight OpEx control, installed base and installations (20%) increased, and CORIS reached important regulatory and controlled release milestones. Headwinds cited were mostly external or transitional — FX volatility caused reported EBIT/PBT to dip slightly, gross margins were modestly compressed by tariffs, airfreight and product mix, and CORIS commercialization is driving incremental OpEx and near-term inventory investment. Overall, the company reaffirmed FY26 guidance (8–12% revenue growth at constant currency) and conveyed clear execution plans and balance-sheet strength, leaving the balance of information as net positive.View all AU:NAN earnings summariesNAN Stock 12 Month Forecast
Average Price Target
AU$4.21
▲(12.15% Upside)
Technical Analysis
SDI Limited
―
Austco Healthcare Limited
―
Cyclopharm Limited
―
Trajan Group Holdings Ltd
―
Aroa Biosurgery Ltd
―
Options Prices
Currently, No data available
---